Patents by Inventor Melvin J. Yu

Melvin J. Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for use in treating cancer
    Patent number: 8148554
    Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer, and intermediates for the synthesis of such compositions.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: April 3, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Boris M. Seletsky, Melvin J. Yu, Wanjun Zheng
  • Methods and compositions for use in treating cancer
    Patent number: 8097648
    Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: January 17, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Bruce A. Littlefield, Murray J. Towle, Boris M. Seletsky, Melvin J. Yu, Wanjun Zheng
  • METHODS AND COMPOSITIONS FOR USE IN TREATING CANCER
    Publication number: 20110172446
    Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer, and intermediates for the synthesis of such compositions.
    Type: Application
    Filed: August 12, 2010
    Publication date: July 14, 2011
    Inventors: Bruce A. Littlefield, Boris M. Seletsky, Murray J. Towle, Melvin J. Yu, Wanjun Zheng
  • Intermediates in the preparation of macrocyclic analogs
    Patent number: 6469182
    Abstract: Novel intermediates of the formula They are used in the preparation of macrocyclic analogs.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: October 22, 2002
    Assignee: Eisai Co., Ltd.
    Inventors: Bruce A. Littlefield, Monica H. Palme, Boris M. Seletsky, Murray J. Towle, Melvin J. Yu, Wanjun Zheng
  • Intermediate compounds for preparing macrocylcic analogs
    Patent number: 6365759
    Abstract: Intermediate compounds of the formulas for use in the preparation of macrocyclic analogs.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: April 2, 2002
    Assignee: Eisai Co., Ltd.
    Inventors: Bruce A. Littlefield, Monica H. Palme, Boris M. Seletsky, Murray J. Towle, Melvin J. Yu, Wanjun Zheng
  • Macrocyclic analogs and methods of their use and preparation
    Patent number: 6214865
    Abstract: The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: April 10, 2001
    Assignee: Eisai Co., Ltd.
    Inventors: Bruce A. Littlefield, Monica H. Palme, Boris M. Seletsky, Murray J. Towle, Melvin J. Yu, Wanjun Zheng
  • 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof
    Patent number: 5196427
    Abstract: Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Melvin J. Yu, Jefferson R. McCowan, K. Jeff Thrasher
  • 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
    Patent number: 5075313
    Abstract: Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: December 24, 1991
    Assignee: Eli Lilly and Company
    Inventors: Melvin J. Yu, Jefferson R. McCowan, K. Jeff Thrasher